SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-076997
Filing Date
2021-03-11
Accepted
2021-03-11 07:09:55
Documents
17
Period of Report
2021-03-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d28892d8k.htm   iXBRL 8-K 29337
2 EX-5.1 d28892dex51.htm EX-5.1 6670
3 EX-10.1 d28892dex101.htm EX-10.1 111315
4 EX-99.1 d28892dex991.htm EX-99.1 8172
8 GRAPHIC g28892g41g64.jpg GRAPHIC 6293
9 GRAPHIC g28892img1.jpg GRAPHIC 3386
  Complete submission text file 0001193125-21-076997.txt   335639

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA xers-20210311.xsd EX-101.SCH 3078
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE xers-20210311_lab.xml EX-101.LAB 18887
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xers-20210311_pre.xml EX-101.PRE 11865
10 EXTRACTED XBRL INSTANCE DOCUMENT d28892d8k_htm.xml XML 3529
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 21731832
SIC: 2834 Pharmaceutical Preparations